Fluciclovine

TargetMol
Product Code: TAR-T31812
Supplier: TargetMol
CodeSizePrice
TAR-T31812-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Fluciclovine is a PET chemical compound designed for the testing of disease threats.
CAS:
222727-43-7
Formula:
C5H8FNO2
Molecular Weight:
133.122
Purity:
0.98
SMILES:
N[C@@]1(C[C@H](F)C1)C(O)=O

References

1. Nanni C, Schiavina R, Brunocilla E, Boschi S, Borghesi M, Zanoni L, Pettinato C, Martorana G, Fanti S. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT. Clin Nucl Med. 2015 Aug;40(8):e386-91. doi: 10.1097/RLU.0000000000000849. PubMed PMID: 26053708. 2. Odewole OA, Tade FI, Nieh PT, Savir-Baruch B, Jani AB, Master VA, Rossi PJ, Halkar RK, Osunkoya AO, Akin-Akintayo O, Zhang C, Chen Z, Goodman MM, Schuster DM. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83. doi: 10.1007/s00259-016-3383-8. Epub 2016 Apr 18. PubMed PMID: 27091135; PubMed Central PMCID: PMC4970909. 3. Ono M, Oka S, Okudaira H, Nakanishi T, Mizokami A, Kobayashi M, Schuster DM, Goodman MM, Shirakami Y, Kawai K. [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells. Nucl Med Biol. 2015 Nov;42(11):887-92. doi: 10.1016/j.nucmedbio.2015.07.005. Epub 2015 Jul 15. PubMed PMID: 26278491. 4. Schreibmann E, Schuster DM, Rossi PJ, Shelton J, Cooper S, Jani AB. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial. Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):206-13. doi: 10.1016/j.ijrobp.2016.04.023. Epub 2016 Apr 30. PubMed PMID: 27511856; PubMed Central PMCID: PMC5645084.